North Star Investment Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-250
| Closed | -$330 | – | 1282 |
|
|
2024
Q3 | $330 | Hold |
250
| – | – | ﹤0.01% | 1142 |
|
|
2024
Q2 | $1.9K | Hold |
250
| – | – | ﹤0.01% | 1041 |
|
|
2024
Q1 | $2.25K | Hold |
250
| – | – | ﹤0.01% | 1078 |
|
|
2023
Q4 | $2.68K | Sell |
250
-250
| -50% | -$1.8K | ﹤0.01% | 1019 |
|
|
2023
Q3 | $3K | Buy |
500
+250
| +100% | +$1.76K | ﹤0.01% | 1026 |
|
|
2023
Q2 | $1.73K | Hold |
250
| – | – | ﹤0.01% | 1088 |
|
|
2023
Q1 | $3.92K | Hold |
250
| – | – | ﹤0.01% | 1012 |
|
|
2022
Q4 | $5K | Hold |
250
| – | – | ﹤0.01% | 971 |
|
|
2022
Q3 | $4K | Hold |
250
| – | – | ﹤0.01% | 979 |
|
|
2022
Q2 | $6K | Hold |
250
| – | – | ﹤0.01% | 923 |
|
|
2022
Q1 | $7K | Hold |
250
| – | – | ﹤0.01% | 940 |
|
|
2021
Q4 | $11K | Hold |
250
| – | – | ﹤0.01% | 895 |
|
|
2021
Q3 | $21K | Hold |
250
| – | – | ﹤0.01% | 736 |
|
|
2021
Q2 | $24K | Hold |
250
| – | – | ﹤0.01% | 717 |
|
|
2021
Q1 | $42K | Hold |
250
| – | – | ﹤0.01% | 584 |
|
|
2020
Q4 | $24K | Buy |
250
+50
| +25% | +$3.16K | ﹤0.01% | 663 |
|
|
2020
Q3 | $7K | Hold |
200
| – | – | ﹤0.01% | 814 |
|
|
2020
Q2 | $11K | Hold |
200
| – | – | ﹤0.01% | 713 |
|
|
2020
Q1 | $12K | Sell |
200
-45
| -18% | -$3.36K | ﹤0.01% | 706 |
|
|
2019
Q4 | $19K | Hold |
245
| – | – | ﹤0.01% | 721 |
|
|
2019
Q3 | $24K | Buy |
+245
| New | +$25.1K | ﹤0.01% | 688 |
|
Other funds holding ONCT
North Star Investment Management's ONCT Position: Q4 2024 in Review
North Star Investment Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 250 shares — an estimated $330 sold.
North Star Investment Management first reported a position in ONCT in Q3 2019 and held it in 21 quarters. The position peaked at $42K in Q1 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.
- North Star Investment Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- North Star Investment Management sold 250 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $330.
- North Star Investment Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2019 and held it in 21 quarters.
- North Star Investment Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $42K in Q1 2021.
- 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.
Based on North Star Investment Management's 13F filing for Q4 2024, filed 10 Feb 2025.